HRP970410A2 - Butyric acid matrix metalloproteinase inhibitors - Google Patents

Butyric acid matrix metalloproteinase inhibitors

Info

Publication number: HRP970410A2
Authority: HR; Croatia
Prior art keywords: oxo; butyric acid; dibenzofuran; compound; amino
Prior art date: 1996-08-16

Application number

HR60/024,025A

Other languages

English (en)

Croatian (hr)

Inventor

Joseph Armant Picard

Original Assignee

Joseph Armant Picard

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-16

Filing date

1997-07-23

Publication date

1998-08-31

1997-07-23 Application filed by Joseph Armant Picard filed Critical Joseph Armant Picard

1998-08-31 Publication of HRP970410A2 publication Critical patent/HRP970410A2/hr

Links

239000003771 matrix metalloproteinase inhibitor Substances 0.000 title description 2
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 title 2
239000001257 hydrogen Substances 0.000 claims abstract description 29
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 29
229910052760 oxygen Inorganic materials 0.000 claims abstract description 20
229910052717 sulfur Inorganic materials 0.000 claims abstract description 20
102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 19
108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 19
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 11
125000000217 alkyl group Chemical group 0.000 claims abstract description 10
230000002401 inhibitory effect Effects 0.000 claims abstract description 8
125000003118 aryl group Chemical group 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 110
-1 4-dibenzofuran-2-yl-2-(3,4-dichloro-benzoylamino)-4-oxo-butyric acid Chemical compound 0.000 claims description 86
238000000034 method Methods 0.000 claims description 27
125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 12
125000001072 heteroaryl group Chemical group 0.000 claims description 12
150000002431 hydrogen Chemical class 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 8
NUZCSVKFVKXZEM-LBPRGKRZSA-N (2s)-4-dibenzofuran-2-yl-4-oxo-2-[(2,2,2-trifluoroacetyl)amino]butanoic acid Chemical group C1=CC=C2C3=CC(C(=O)C[C@@H](C(=O)O)NC(=O)C(F)(F)F)=CC=C3OC2=C1 NUZCSVKFVKXZEM-LBPRGKRZSA-N 0.000 claims description 7
125000000753 cycloalkyl group Chemical group 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
101100134925 Gallus gallus COR6 gene Proteins 0.000 claims description 6
206010003246 arthritis Diseases 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 5
DCXSZYLYDZGFMN-LBPRGKRZSA-N (2s)-2-amino-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)C[C@H](N)C(O)=O)=CC=C3OC2=C1 DCXSZYLYDZGFMN-LBPRGKRZSA-N 0.000 claims description 4
208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
239000012453 solvate Substances 0.000 claims description 4
NUZCSVKFVKXZEM-GFCCVEGCSA-N (2r)-4-dibenzofuran-2-yl-4-oxo-2-[(2,2,2-trifluoroacetyl)amino]butanoic acid Chemical group C1=CC=C2C3=CC(C(=O)C[C@H](C(=O)O)NC(=O)C(F)(F)F)=CC=C3OC2=C1 NUZCSVKFVKXZEM-GFCCVEGCSA-N 0.000 claims description 3
125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 3
208000007474 aortic aneurysm Diseases 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
208000028169 periodontal disease Diseases 0.000 claims description 3
230000029663 wound healing Effects 0.000 claims description 3
MCBFGLOCAYSWIG-IBGZPJMESA-N (2s)-4-dibenzofuran-2-yl-2-(octanoylamino)-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)C[C@H](NC(=O)CCCCCCC)C(O)=O)=CC=C3OC2=C1 MCBFGLOCAYSWIG-IBGZPJMESA-N 0.000 claims description 2
LWMATGKIVQPBTO-FQEVSTJZSA-N (2s)-4-dibenzofuran-2-yl-4-oxo-2-(3-phenylpropanoylamino)butanoic acid Chemical compound N([C@@H](CC(=O)C=1C=C2C3=CC=CC=C3OC2=CC=1)C(=O)O)C(=O)CCC1=CC=CC=C1 LWMATGKIVQPBTO-FQEVSTJZSA-N 0.000 claims description 2
BBIUWUFUMFZBLS-DEOSSOPVSA-N (2s)-4-dibenzofuran-2-yl-4-oxo-2-(7-phenylheptanoylamino)butanoic acid Chemical compound N([C@@H](CC(=O)C=1C=C2C3=CC=CC=C3OC2=CC=1)C(=O)O)C(=O)CCCCCCC1=CC=CC=C1 BBIUWUFUMFZBLS-DEOSSOPVSA-N 0.000 claims description 2
NMCAXOLGEVSANY-IBGZPJMESA-N (2s)-4-dibenzofuran-2-yl-4-oxo-2-[(2-phenylacetyl)amino]butanoic acid Chemical compound N([C@@H](CC(=O)C=1C=C2C3=CC=CC=C3OC2=CC=1)C(=O)O)C(=O)CC1=CC=CC=C1 NMCAXOLGEVSANY-IBGZPJMESA-N 0.000 claims description 2
DTTSJWNGBWEGJL-DEOSSOPVSA-N (2s)-4-dibenzofuran-2-yl-4-oxo-2-[(4-phenylbenzoyl)amino]butanoic acid Chemical compound N([C@@H](CC(=O)C=1C=C2C3=CC=CC=C3OC2=CC=1)C(=O)O)C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 DTTSJWNGBWEGJL-DEOSSOPVSA-N 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
ZHMTXQMPTXZPIY-QHCPKHFHSA-N (2s)-4-dibenzofuran-2-yl-2-(dodecanoylamino)-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)C[C@H](NC(=O)CCCCCCCCCCC)C(O)=O)=CC=C3OC2=C1 ZHMTXQMPTXZPIY-QHCPKHFHSA-N 0.000 claims 1
HMMCXHVGTKAARV-UHFFFAOYSA-N 2-(1,3-benzodioxole-5-carbonylamino)-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=C2OCOC2=CC(C(=O)NC(CC(=O)C=2C=C3C4=CC=CC=C4OC3=CC=2)C(=O)O)=C1 HMMCXHVGTKAARV-UHFFFAOYSA-N 0.000 claims 1
HASXPTMFXLKZKB-UHFFFAOYSA-N 2-(adamantane-1-carbonylamino)-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)NC(C(=O)O)CC(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 HASXPTMFXLKZKB-UHFFFAOYSA-N 0.000 claims 1
UXDFOPWGKCLXHB-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1CCCCC1 UXDFOPWGKCLXHB-UHFFFAOYSA-N 0.000 claims 1
GWMJIXUSSXSMRG-UHFFFAOYSA-N 2-(cyclopentanecarbonylamino)-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1CCCC1 GWMJIXUSSXSMRG-UHFFFAOYSA-N 0.000 claims 1
QMGUDKMWDWCBCQ-UHFFFAOYSA-N 2-(cyclopropanecarbonylamino)-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1CC1 QMGUDKMWDWCBCQ-UHFFFAOYSA-N 0.000 claims 1
IAUWMCHCESSGHL-UHFFFAOYSA-N 2-[(4-bromobenzoyl)amino]-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=C(Br)C=C1 IAUWMCHCESSGHL-UHFFFAOYSA-N 0.000 claims 1
VHHBVCKJVFFDSS-UHFFFAOYSA-N 2-[(4-butylbenzoyl)amino]-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC(CCCC)=CC=C1C(=O)NC(C(O)=O)CC(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 VHHBVCKJVFFDSS-UHFFFAOYSA-N 0.000 claims 1
HUJUWEKZEQREME-UHFFFAOYSA-N 2-[(4-chlorobenzoyl)amino]-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 HUJUWEKZEQREME-UHFFFAOYSA-N 0.000 claims 1
CREGTWRJJNAHQG-UHFFFAOYSA-N 2-[(4-cyanobenzoyl)amino]-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=C(C#N)C=C1 CREGTWRJJNAHQG-UHFFFAOYSA-N 0.000 claims 1
UTVGLHADICPSSD-UHFFFAOYSA-N 2-[4-(4-bromophenyl)butanoylamino]-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)CCCC1=CC=C(Br)C=C1 UTVGLHADICPSSD-UHFFFAOYSA-N 0.000 claims 1
MXXFRVNFZOBQEA-UHFFFAOYSA-N 2-[[2-(4-chlorophenoxy)acetyl]amino]-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)COC1=CC=C(Cl)C=C1 MXXFRVNFZOBQEA-UHFFFAOYSA-N 0.000 claims 1
MAUSDPNSKAJRAU-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-(2,2-dimethylpentanoylamino)-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CC(NC(=O)C(C)(C)CCC)C(O)=O)=CC=C3OC2=C1 MAUSDPNSKAJRAU-UHFFFAOYSA-N 0.000 claims 1
JISXRAXWLHYCBR-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-(furan-2-carbonylamino)-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=CO1 JISXRAXWLHYCBR-UHFFFAOYSA-N 0.000 claims 1
WFNXXSWVNGQMDP-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-(heptanoylamino)-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CC(NC(=O)CCCCCC)C(O)=O)=CC=C3OC2=C1 WFNXXSWVNGQMDP-UHFFFAOYSA-N 0.000 claims 1
AKGXVDYGGPDGJB-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-(naphthalene-2-carbonylamino)-4-oxobutanoic acid Chemical compound C1=CC=CC2=CC(C(=O)NC(CC(=O)C=3C=C4C5=CC=CC=C5OC4=CC=3)C(=O)O)=CC=C21 AKGXVDYGGPDGJB-UHFFFAOYSA-N 0.000 claims 1
ISLYILJAMSURDT-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-[(2,2-diphenylacetyl)amino]-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ISLYILJAMSURDT-UHFFFAOYSA-N 0.000 claims 1
GKCMMGCOHRRRFU-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-[(3,4-dimethoxybenzoyl)amino]-4-oxobutanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC(C(O)=O)CC(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 GKCMMGCOHRRRFU-UHFFFAOYSA-N 0.000 claims 1
XKNLHOFJVPPFQT-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-[(4-fluorobenzoyl)amino]-4-oxobutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=C(F)C=C1 XKNLHOFJVPPFQT-UHFFFAOYSA-N 0.000 claims 1
ZYNFIARWEIOWNN-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-[(4-methylbenzoyl)amino]-4-oxobutanoic acid Chemical compound C1=CC(C)=CC=C1C(=O)NC(C(O)=O)CC(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 ZYNFIARWEIOWNN-UHFFFAOYSA-N 0.000 claims 1
KBXCQKVSWISGFJ-UHFFFAOYSA-N 4-dibenzofuran-2-yl-2-[[2-(3,4-dimethoxyphenyl)acetyl]amino]-4-oxobutanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NC(C(O)=O)CC(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 KBXCQKVSWISGFJ-UHFFFAOYSA-N 0.000 claims 1
ITMGYNMHQAJYDJ-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoylamino)butanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CC(C(=O)O)NC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)=CC=C3OC2=C1 ITMGYNMHQAJYDJ-UHFFFAOYSA-N 0.000 claims 1
BZIWHFIMRGOBIT-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(2-phenoxypropanoylamino)butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(O)=O)NC(=O)C(C)OC1=CC=CC=C1 BZIWHFIMRGOBIT-UHFFFAOYSA-N 0.000 claims 1
IEYMDUDPYODVMS-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(2-phenylbutanoylamino)butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(O)=O)NC(=O)C(CC)C1=CC=CC=C1 IEYMDUDPYODVMS-UHFFFAOYSA-N 0.000 claims 1
PJLGAMHTQUZYGU-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(3-phenylprop-2-enoylamino)butanoic acid Chemical group C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C=CC1=CC=CC=C1 PJLGAMHTQUZYGU-UHFFFAOYSA-N 0.000 claims 1
SAXKXTMKPHBRFQ-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(pyridine-2-carbonylamino)butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=CC=N1 SAXKXTMKPHBRFQ-UHFFFAOYSA-N 0.000 claims 1
PMUUSSWBQQAGDP-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(pyridine-4-carbonylamino)butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=NC=C1 PMUUSSWBQQAGDP-UHFFFAOYSA-N 0.000 claims 1
ADOQKCFUCHLNGM-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(quinoxaline-2-carbonylamino)butanoic acid Chemical compound C1=CC=CC2=NC(C(=O)NC(CC(=O)C=3C=C4C5=CC=CC=C5OC4=CC=3)C(=O)O)=CN=C21 ADOQKCFUCHLNGM-UHFFFAOYSA-N 0.000 claims 1
UQLILBNWYVUXJH-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-(thiophene-2-carbonylamino)butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=CC=CS1 UQLILBNWYVUXJH-UHFFFAOYSA-N 0.000 claims 1
JAFDGIOTAZMZJS-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-[(2,3,4,5,6-pentafluorobenzoyl)amino]butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F JAFDGIOTAZMZJS-UHFFFAOYSA-N 0.000 claims 1
WCOPGDBARTUQMG-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-[(2-phenoxyacetyl)amino]butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)COC1=CC=CC=C1 WCOPGDBARTUQMG-UHFFFAOYSA-N 0.000 claims 1
CDTUVUWJAKBTBC-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-[(2-phenylmethoxyacetyl)amino]butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)COCC1=CC=CC=C1 CDTUVUWJAKBTBC-UHFFFAOYSA-N 0.000 claims 1
FBBNDBMGOOWVNN-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxo-2-[(2-thiophen-2-ylacetyl)amino]butanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1C(=O)CC(C(=O)O)NC(=O)CC1=CC=CS1 FBBNDBMGOOWVNN-UHFFFAOYSA-N 0.000 claims 1
125000003860 C1-C20 alkoxy group Chemical group 0.000 claims 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
201000010099 disease Diseases 0.000 abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
125000000547 substituted alkyl group Chemical group 0.000 abstract description 6
210000002808 connective tissue Anatomy 0.000 abstract description 5
125000003545 alkoxy group Chemical group 0.000 abstract description 2
230000015556 catabolic process Effects 0.000 abstract description 2
241001465754 Metazoa Species 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
239000000243 solution Substances 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 19
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
238000002844 melting Methods 0.000 description 15
239000007787 solid Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
230000008018 melting Effects 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
150000003141 primary amines Chemical class 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
239000000047 product Substances 0.000 description 8
239000000758 substrate Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
230000007062 hydrolysis Effects 0.000 description 7
238000006460 hydrolysis reaction Methods 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
230000006378 damage Effects 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
239000002775 capsule Substances 0.000 description 5
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
206010027476 Metastases Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
229940014800 succinic anhydride Drugs 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
101100134927 Gallus gallus COR8 gene Proteins 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
206010064996 Ulcerative keratitis Diseases 0.000 description 3
230000010933 acylation Effects 0.000 description 3
238000005917 acylation reaction Methods 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
150000004657 carbamic acid derivatives Chemical class 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000003301 hydrolyzing effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
VBBUFMFZDHLELS-UHFFFAOYSA-N n-(oxomethylidene)carbamoyl chloride Chemical compound ClC(=O)N=C=O VBBUFMFZDHLELS-UHFFFAOYSA-N 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
235000011121 sodium hydroxide Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 3
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
230000005747 tumor angiogenesis Effects 0.000 description 3
UNMOEOGLHTZYSU-ZDUSSCGKSA-N (2s)-4-dibenzofuran-2-yl-4-hydroxyimino-2-[(2,2,2-trifluoroacetyl)amino]butanoic acid Chemical compound C1=CC=C2C3=CC(C(C[C@H](NC(=O)C(F)(F)F)C(O)=O)=NO)=CC=C3OC2=C1 UNMOEOGLHTZYSU-ZDUSSCGKSA-N 0.000 description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102100027995 Collagenase 3 Human genes 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102100030417 Matrilysin Human genes 0.000 description 2
108090000855 Matrilysin Proteins 0.000 description 2
108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
102100030416 Stromelysin-1 Human genes 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
150000004648 butanoic acid derivatives Chemical class 0.000 description 2
150000001656 butanoic acid esters Chemical class 0.000 description 2
235000014121 butter Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
235000013877 carbamide Nutrition 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
125000004663 dialkyl amino group Chemical group 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical group 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
150000003585 thioureas Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
150000003672 ureas Chemical class 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
AWTBTVNHZFPSBT-AWEZNQCLSA-N (2s)-2-acetamido-4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)C[C@H](NC(=O)C)C(O)=O)=CC=C3OC2=C1 AWTBTVNHZFPSBT-AWEZNQCLSA-N 0.000 description 1
CVEUKLDHJDVUJU-ZDUSSCGKSA-N (2s)-4-dibenzofuran-2-yl-2-(methanesulfonamido)-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)C[C@H](NS(=O)(=O)C)C(O)=O)=CC=C3OC2=C1 CVEUKLDHJDVUJU-ZDUSSCGKSA-N 0.000 description 1
NWBOXXZCMBLCLP-IBGZPJMESA-N (2s)-4-dibenzofuran-2-yl-2-[(4-methylphenyl)sulfonylamino]-4-oxobutanoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(O)=O)CC(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 NWBOXXZCMBLCLP-IBGZPJMESA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
CFGNAXJGEKHSPQ-UHFFFAOYSA-N 2-aminoacetyl bromide Chemical compound NCC(Br)=O CFGNAXJGEKHSPQ-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
OJIYIEMQXPBGTA-UHFFFAOYSA-N 2-dibenzofuran-1-ylbutanoic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(C(O)=O)CC OJIYIEMQXPBGTA-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
FEUFNKALUGDEMQ-UHFFFAOYSA-N 2-isocyanato-1,3-di(propan-2-yl)benzene Chemical compound CC(C)C1=CC=CC(C(C)C)=C1N=C=O FEUFNKALUGDEMQ-UHFFFAOYSA-N 0.000 description 1
HBZSTRIPIRCTOW-UHFFFAOYSA-N 2-morpholin-2-ylethanesulfonic acid hydrate Chemical compound O.OS(=O)(=O)CCC1CNCCO1 HBZSTRIPIRCTOW-UHFFFAOYSA-N 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
QUBJDMPBDURTJT-UHFFFAOYSA-N 3-chlorothiophene Chemical group ClC=1C=CSC=1 QUBJDMPBDURTJT-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
FAUKZJSCBIVZGJ-UHFFFAOYSA-N 3-nitromorpholine Chemical compound [O-][N+](=O)C1COCCN1 FAUKZJSCBIVZGJ-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 1
101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108050005238 Collagenase 3 Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
102000056189 Neutrophil collagenases Human genes 0.000 description 1
108030001564 Neutrophil collagenases Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101710108790 Stromelysin-1 Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000001980 alanyl group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000005037 alkyl phenyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229920003180 amino resin Polymers 0.000 description 1
125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
238000009835 boiling Methods 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
MPAYEWNVIPXRDP-UHFFFAOYSA-N ethanimine Chemical compound CC=N MPAYEWNVIPXRDP-UHFFFAOYSA-N 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000011491 glass wool Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
239000010410 layer Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
125000001288 lysyl group Chemical group 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
229940102396 methyl bromide Drugs 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
238000005897 peptide coupling reaction Methods 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
MCJXDWRORUZWER-UHFFFAOYSA-N phenylmethanesulfonyl bromide Chemical compound BrS(=O)(=O)CC1=CC=CC=C1 MCJXDWRORUZWER-UHFFFAOYSA-N 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
238000010791 quenching Methods 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940087562 sodium acetate trihydrate Drugs 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
125000005415 substituted alkoxy group Chemical group 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
150000003461 sulfonyl halides Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000003556 thioamides Chemical class 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
239000011345 viscous material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Lubricants (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Furan Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Enzymes And Modification Thereof (AREA)

HR60/024,025A 1996-08-16 1997-07-23 Butyric acid matrix metalloproteinase inhibitors HRP970410A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2402596P	1996-08-16	1996-08-16

Publications (1)

Publication Number	Publication Date
HRP970410A2 true HRP970410A2 (en)	1998-08-31

Family

ID=21818459

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR60/024,025A HRP970410A2 (en)	1996-08-16	1997-07-23	Butyric acid matrix metalloproteinase inhibitors

Country Status (11)

Country	Link
US (1)	US6020366A (de)
EP (1)	EP0923569B1 (de)
JP (1)	JP2000516607A (de)
AT (1)	ATE282602T1 (de)
AU (1)	AU3729397A (de)
CO (1)	CO4900041A1 (de)
DE (1)	DE69731642T2 (de)
ES (1)	ES2231879T3 (de)
HR (1)	HRP970410A2 (de)
WO (1)	WO1998006711A1 (de)
ZA (1)	ZA977328B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3729397A (en) *	1996-08-16	1998-03-06	Warner-Lambert Company	Butyric acid matrix metalloproteinase inhibitors
OA11589A (en)	1998-07-30	2004-07-30	Warner Lambert Co	Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.
US6350885B1 (en)	1998-07-30	2002-02-26	Warner-Lambert Company	Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
US7325009B1 (en)	2000-06-30	2008-01-29	Brightpoint, Inc.	Customer-controlled inventory access
AU2003300379A1 (en) *	2002-12-27	2004-07-29	Angiotech Pharmaceuticals, Inc.	Compositions and methods of using collagen and MMPI
WO2004060346A2 (en)	2002-12-30	2004-07-22	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
CN109996541A (zh) *	2016-09-07	2019-07-09	普利安特治疗公司	N-酰基氨基酸化合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE54551B1 (en) *	1982-01-22	1989-11-22	Ici Plc	Amide derivatives
US5114953A (en) *	1990-11-21	1992-05-19	University Of Florida	Treatment for tissue ulceration
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
AU690703B2 (en) *	1994-06-22	1998-04-30	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
US5665764A (en) *	1995-06-02	1997-09-09	Warner-Lambert Company	Tricyclic inhibitors of matrix metalloproteinases
AU3729397A (en) *	1996-08-16	1998-03-06	Warner-Lambert Company	Butyric acid matrix metalloproteinase inhibitors

1997
- 1997-07-16 AU AU37293/97A patent/AU3729397A/en not_active Abandoned
- 1997-07-16 US US09/171,833 patent/US6020366A/en not_active Expired - Fee Related
- 1997-07-16 DE DE69731642T patent/DE69731642T2/de not_active Expired - Fee Related
- 1997-07-16 AT AT97934175T patent/ATE282602T1/de not_active IP Right Cessation
- 1997-07-16 ES ES97934175T patent/ES2231879T3/es not_active Expired - Lifetime
- 1997-07-16 EP EP97934175A patent/EP0923569B1/de not_active Expired - Lifetime
- 1997-07-16 WO PCT/US1997/012389 patent/WO1998006711A1/en not_active Ceased
- 1997-07-16 JP JP10509712A patent/JP2000516607A/ja not_active Abandoned
- 1997-07-23 HR HR60/024,025A patent/HRP970410A2/hr not_active Application Discontinuation
- 1997-08-14 ZA ZA9707328A patent/ZA977328B/xx unknown
- 1997-08-15 CO CO97047221A patent/CO4900041A1/es unknown

Also Published As

Publication number	Publication date
EP0923569B1 (de)	2004-11-17
DE69731642D1 (de)	2004-12-23
JP2000516607A (ja)	2000-12-12
US6020366A (en)	2000-02-01
AU3729397A (en)	1998-03-06
ZA977328B (en)	1998-02-19
ATE282602T1 (de)	2004-12-15
WO1998006711A1 (en)	1998-02-19
ES2231879T3 (es)	2005-05-16
CO4900041A1 (es)	2000-03-27
EP0923569A1 (de)	1999-06-23
DE69731642T2 (de)	2005-12-01

Legal Events

Date	Code	Title
1998-08-31	A1OB	Publication of a patent application
1999-02-26	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2005-09-19	ODBC	Application rejected

Publication	Publication Date	Title
EP0934267B1 (de)	2002-01-30	Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
RU2059637C1 (ru)	1996-05-10	Гетероциклические производные замещенных 2-ациламино-5-тиазолов, способы их получения, производное замещенного 2-аминотиазола, производные 2-амино-4-фенилтиазола
ES2250591T3 (es)	2006-04-16	Derivados de heteroarilo sustituidos con diacidos como inhibidores de metaloproteinasas de la matriz.
KR100438633B1 (ko)	2004-07-02	Ｎ-(3-벤조푸라닐)우레아 유도체
AU700725B2 (en)	1999-01-14	Matrix metalloprotease inhibitors
KR100637110B1 (ko)	2006-10-23	세포 유착 억제제
EP0901466B1 (de)	2001-10-31	Biphenylsulfonamid matrix metalloproteinase inhibitoren
AU8270898A (en)	1999-01-19	Antithrombotic agents
MXPA03006598A (es)	2004-10-15	Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz.
AU8237698A (en)	1999-02-22	Acyclic metalloprotease inhibitors
CA2268098A1 (en)	1998-04-23	Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
CZ36899A3 (cs)	1999-07-14	Deriváty hydroxamové a karboxylové kyseliny a jejich použití
CA2375920A1 (en)	2000-12-21	Compounds
JP2003528079A (ja)	2003-09-24	複素環式側鎖含有メタロプロテアーゼ阻害剤
HK1048468B (en)	2005-07-29	Derivatives and their use in other applications for the treatment of osteoporosis
EP0769498A1 (de)	1997-04-23	Sulfonamide mit Elastase inhibierender Wirkung
AU9788298A (en)	1999-04-27	Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
EP0923569B1 (de)	2004-11-17	Buttersäure matrix-metalloproteinase-inhibitoren
JP2002542228A (ja)	2002-12-10	Ｍｍｐ阻害剤
PL198827B1 (pl)	2008-07-31	ω-Amidy N-arylosulfonyloaminokwasów, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie ω-amidów N-arylosulfonyloaminokwasów
ES2222711T3 (es)	2005-02-01	Derivados de acido hidroxamico como inhibidores de la produccion de cd23 humano y de la liberacion de tnf.
CA1295333C (en)	1992-02-04	Acylaminoalkanoyl compounds
EP1270569A1 (de)	2003-01-02	Substituierte tryptophanderivate
KR100242266B1 (ko)	2000-02-01	캄포 구조를 갖는 신규한 트롬빈 억제제
KR100242264B1 (ko)	2000-02-01	N-알킬-n-알콕시아민 구조를 갖는 신규한 트롬빈 억제제